Semaglutide Cuts Heavy Drinking Days in Lancet AUD Trial
A 108-patient Copenhagen trial published in The Lancet found weekly semaglutide on top of CBT cut heavy drinking days 13.7 points more than placebo over 26 weeks.
May 7, 2026 · 3 min read
A randomized, double-blind trial published in The Lancet found that once-weekly semaglutide added to cognitive behavioral therapy reduced heavy drinking days by 13.7 percentage points more than placebo over 26 weeks — the strongest controlled-trial evidence yet that a GLP-1 can move the needle on alcohol use disorder.
What happened
Researchers at Copenhagen University Hospital, led by Mette Kruse Klausen and Anders Fink-Jensen, randomized 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and comorbid obesity to weekly semaglutide 2.4 mg (the Wegovy dose) or placebo, on top of standard CBT. The primary endpoint was change in heavy drinking days at 26 weeks.
The semaglutide group's heavy drinking days fell 41.1 percentage points from baseline versus 26.4 points in the placebo group — a between-group difference of 13.7 points (P=0.0015). Average monthly alcohol consumption fell from baseline to about 1,550 grams in the placebo group and roughly 1,026 grams with semaglutide, and daily drink counts dropped 3.5 units on the drug versus 2.1 on placebo.
The number needed to treat was 4.3, compared with 7-or-higher for currently approved AUD medications such as naltrexone and acamprosate. Both groups also lost weight, with the semaglutide arm losing more — consistent with the drug's known effect.
Why it matters
This is the first randomized controlled trial to show a clinically meaningful effect of a GLP-1 on alcohol intake at a dose that's already approved and prescribed for weight management. Earlier observational signals from electronic health records pointed in the same direction; the Lancet trial confirms it under blinded conditions.
Three caveats temper the enthusiasm. The trial enrolled patients who had both AUD and obesity, so generalizability to AUD without obesity is unproven. The sample size of 108 is modest. And the trial was 26 weeks — long enough to show acute effect, but not long enough to address relapse rates after discontinuation.
Even with those caveats, the NNT of 4.3 is substantially better than existing approved AUD drugs. For patients already on semaglutide for weight loss who also have problematic drinking, the implication is that the drug may already be helping more than they realize. For background on how GLP-1s and alcohol intersect, see our cluster on semaglutide and alcohol.
What to watch
A larger Phase 3 program would be the natural next step, but neither Novo Nordisk nor an independent sponsor has publicly committed to one. Off-label prescribing is likely to accelerate regardless — addiction medicine specialists were already prescribing low-dose semaglutide on the strength of observational data, and a Lancet RCT will broaden that.
The other thing to watch is whether the FDA signals openness to an AUD label expansion. Historically the agency has required at least two pivotal trials for new addiction indications; one Copenhagen study won't get there alone.
Sources
Sources